HomeInsightsStock Comparison

Emcure Pharmaceuticals Ltd vs Krebs Biochemicals Industries Ltd Stock Comparison

Emcure Pharmaceuticals Ltd vs Krebs Biochemicals Industries Ltd Stock Comparison

Last Updated on: May 11, 2025

Key Highlights

  • The Latest Trading Price of Emcure Pharmaceuticals Ltd is ₹ 1010 as of 09 May 15:30.
  • The P/E Ratio of Emcure Pharmaceuticals Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Krebs Biochemicals & Industries Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The Market Cap of Emcure Pharmaceuticals Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Krebs Biochemicals & Industries Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The revenue of Emcure Pharmaceuticals Ltd for the Dec '24 is ₹ 1959 crore as compare to the Sep '24 revenue of ₹ 2037 crore. This represent the decline of -3.84% The revenue of Krebs Biochemicals & Industries Ltd for the Dec '24 is ₹ 0 crore as compare to the Sep '24 revenue of ₹ 0 crore. This represent the decline of 0%.
  • The ebitda of Emcure Pharmaceuticals Ltd for the Dec '24 is ₹ 358.5 crore as compare to the Sep '24 ebitda of ₹ 416.53 crore. This represent the decline of -13.93% The ebitda of Krebs Biochemicals & Industries Ltd for the Dec '24 is ₹ 0 crore as compare to the Sep '24 ebitda of ₹ 0 crore. This represent the decline of 0%.
  • The net profit of Emcure Pharmaceuticals Ltd changed from ₹ 140.97 crore to ₹ 156.09 crore over 7 quarters. This represents a CAGR of 5.99% The net profit of Krebs Biochemicals & Industries Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% .
  • The Dividend Payout of Emcure Pharmaceuticals Ltd changed from 25.8 % on March 2020 to 22.53 % on March 2024 . This represents a CAGR of -2.67% over 5 yearsThe Dividend Payout of Krebs Biochemicals & Industries Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Emcure Pharmaceuticals Ltd

  • Emcure Pharmaceuticals Limited was originally incorporated as Emcure Pharmaceuticals Private Limited', as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay.
  • Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited', through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001. Emcure Pharmaceuticals an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
  • They are a research and development driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics, which has enabled to reach target markets across over 70 countries, with a strong presence in India, Europe and Canada.

About Krebs Biochemicals & Industries Ltd

  • Krebs Biochemicals & Industries Ltd (Formerly Krebs Biochemicals Ltd), promoted by R T Ravi in 1991 is engaged in the manufacture of Active Pharmaceutical Ingredients(API) through Fermentation process, one among very few in the world to do the same. Krebs develops commercially viable biotech processes for application in medicine, agriculture and industry.
  • Undertaking contract manufacturing for large pharmaceutical and multinational companies and developing products for sale in global markets, the Company possesses expertise and infrastructure in chemical synthesis, fermentation and enzymatic technologies. KBIL which commenced commercial operations in the year 1994 with an installed capacity of 60 TPA has now grown to 150 TPA. KBL went to public with an IPO in 1994. During 2001-02, the company launched Vitamin C(I P Grade) through Fermentation Process.

Emcure Pharmaceuticals Ltd News Hub

News

Emcure Pharma's pune facility receives VAI status from USFDA

The company received the Establishment Inspection Report (EIR) from the USFDA following an...

Read more

21 Apr 2025 11:09

News

Emcure subsidiary Tillomed Laboratories to acquire UK based Manx Healthcare and its subsidiaries

Tillomed Laboratories, a subsidiary of Emcure Pharmaceuticals, has entered into an Asset P...

Read more

04 Apr 2025 12:28

News

Emcure Pharma's European arm acquires Manx Healthcare for '19.7 million

The APA has also been inked with the subsidiaries of Manx, viz. Manx Pharma and Manx Gener...

Read more

04 Apr 2025 14:05

News

Emcutix Biopharmaceuticals inks in-licensing agreement with WiQo

Emcutix Biopharmaceuticals, a wholly owned subsidiary of Emcure Pharmaceuticals, announced...

Read more

02 Apr 2025 10:35

News

Emcure Pharmaceuticals forays into daily supplements space

Emcure Pharmaceuticals announced its entry into the daily supplements space with the expan...

Read more

10 Mar 2025 19:33

News

Emcure Pharma's Maharashtra facility gets 2 USFDA observations

According to an exchange filing, the inspection was conducted at the company's Active Phar...

Read more

26 Feb 2025 13:23

Krebs Biochemicals & Industries Ltd News Hub

News

Krebs Biochemicals & Industries to hold board meeting

Krebs Biochemicals & Industries will hold a meeting of the Board of Directors of the Compa...

Read more

07 May 2025 14:33

News

Krebs Biochemicals & Industries to convene board meeting

Krebs Biochemicals & Industries will hold a meeting of the Board of Directors of the Compa...

Read more

15 Jan 2025 15:28

News

Krebs Biochemicals & Industries Ltd leads losers in 'B' group

Uflex Ltd, Raghav Productivity Enhancers Ltd, Ruby Mills Ltd and Shree Rama Multi-Tech Ltd...

Read more

28 Nov 2024 14:45

News

Krebs Biochemicals & Industries Ltd leads gainers in 'B' group

Ruby Mills Ltd, 3P Land Holdings Ltd, Godavari Biorefineries Ltd and RPP Infra Projects Lt...

Read more

26 Nov 2024 12:15

News

Krebs Biochemicals & Industries to conduct board meeting

Krebs Biochemicals & Industries will hold a meeting of the Board of Directors of the Compa...

Read more

29 Oct 2024 14:40

News

Krebs Biochemicals & Industries schedules AGM

Krebs Biochemicals & Industries announced that the 32th Annual General Meeting (AGM) of th...

Read more

09 Sep 2024 10:11

SWOT Analysis Of Krebs Biochemicals & Industries Ltd

Strength

0

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Krebs Biochemicals & Industries Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Emcure Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Emcure Pharmaceuticals Ltd and Krebs Biochemicals & Industries Ltd

Which company has a larger market capitalization, Emcure Pharmaceuticals Ltd or Krebs Biochemicals & Industries Ltd?

Market cap of Emcure Pharmaceuticals Ltd is 19,139 Cr while Market cap of Krebs Biochemicals & Industries Ltd is 159 Cr

What are the key factors driving the stock performance of Emcure Pharmaceuticals Ltd and Krebs Biochemicals & Industries Ltd?

The stock performance of Emcure Pharmaceuticals Ltd and Krebs Biochemicals & Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Emcure Pharmaceuticals Ltd and Krebs Biochemicals & Industries Ltd?

As of May 11, 2025, the Emcure Pharmaceuticals Ltd stock price is INR ₹1010.1. On the other hand, Krebs Biochemicals & Industries Ltd stock price is INR ₹73.94.

How do dividend payouts of Emcure Pharmaceuticals Ltd and Krebs Biochemicals & Industries Ltd compare?

To compare the dividend payouts of Emcure Pharmaceuticals Ltd and Krebs Biochemicals & Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions